ArticleOncogene2006
Expression of GCIP in transgenic mice decreases susceptibility to chemical hepatocarcinogenesis.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- Cyclin D1 Binding Protein 1 Responds to DNA Damage through the ATM-CHK2 Pathway.Journal of clinical medicine · 2022Article
- CCNDBP1, a Prognostic Marker Regulated by DNA Methylation, Inhibits Aggressive Behavior in Dedifferentiated LiposarcomaFrontiers in oncology · 2021Article
- Evidence for a Role of the Transcriptional Regulator Maid in Tumorigenesis and Aging.PloS one · 2015Article
- GCIP functions as a tumor suppressor in non-small cell lung cancer by suppressing Id1-mediated tumor promotion.Oncotarget · 2014Article
- Notch-1 signaling promotes the malignant features of human breast cancer through NF-κB activation.PloS one · 2014Article
- Structure of a dominant-negative helix-loop-helix transcriptional regulator suggests mechanisms of autoinhibition.The EMBO journal · 2012Article
- Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver.Oncogene · 2010Article
- A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations.Oncogene · 2009Article
- Crystallization and preliminary X-ray diffraction analysis of GCIP/HHM transcriptional regulator.Acta crystallographica. Section F, Structural biology and crystallization communications · 2009Article
- An Id-like molecule, HHM, is a synexpression group-restricted regulator of TGF-beta signalling.The EMBO journal · 2008Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Transcription factors with helix-loop-helix (HLH) motif play critical roles in controlling the expression of genes involved in lineage commitment, cell fate determination, proliferation, and tumorigenesis. To examine whether the newly identified HLH protein GCIP/CCNDBP1 modulates cell fate determination and plays a role in hepatocyte growth, proliferation, and hepatocarcinogenesis, we generated transgenic mice with human GCIP gene driven by a liver-specific albumin promoter. We demonstrated that in GCIP transgenic mice, the overall liver growth and regeneration occurred normally after liver injury induced by carbon tetrachloride (CCl4). In the diethylnitrosamine (DEN)-induced mouse hepatocarcinogenesis, we demonstrated that overexpression of GCIP in mouse liver suppressed DEN-induced hepatocarcinogenesis at an early stage of tumor development. The number of hepatic adenomas at 24 weeks was significantly lower or not detected in GCIP transgenic male mice compared to the control mice under the same treatment. Although GCIP has little inhibition on the number of hepatic tumors at later stages (40 weeks), hepatocellular tumors in GCIP transgenic mice are smaller and well-differentiated compared to the poorly differentiated tumors in wild-type mice. Furthermore, we demonstrate that GCIP functions as a transcriptional suppressor, regulates the expression of cyclin D1, and inhibits anchorage-independent cell growth and colony formation in HepG2 cells, suggesting a significant role of GCIP in tumor initiation and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.